Novartis make White City Place its new UK headquarters

Global pharmaceutical giant Novartis have signed a deal to make White City Place its new UK headquarters.

Joint venture partners Stanhope, Mitsui Fudosan and AIMCo, who own the West London site, confirmed Novartis will initially take 54,000 sq ft of space from March 2019, with the option to expand further to 65,000 sq ft come January 2020.

David Camp, chief executive of Stanhope, said: “We are delighted that Novartis has chosen WestWorks at White City Place as their new headquarters in the UK.

“With the transformation of White City Place and the development of Imperial College’s new campus, White City has confirmed itself as the destination of choice for emerging and advanced life sciences companies.”

Eiichiro Onozawa, managing director of Mitsui Fudosan, said: “Novartis is a huge addition to our rapidly expanding life sciences cluster in WestWorks. The move shows that White City is fast becoming the leading hub at the forefront of innovation for London.”

The JV partners signed Autolus to become the first major life sciences company to take space at White City Place earlier this year and Novartis will also join fellow bio tech firm Synthace at the 1.9m sq ft business, innovation and life sciences district.

Other tenants at White City Place include the Yoox Net-a-Porter technology centre, co-working group Huckletree West, Studio Lagree and F45 Fitness. The WestWorks building is also home to ‘The Studio’, a state of the art 100-seat space with audio and visual recording technology.

“The nature of healthcare and medicine is changing and as we pivot towards becoming a focused medicines company, powered by digital and data, we want to be closer to our customers and partners, and become better networked in the healthcare and life science ecosystem.” said Haseeb Ahmad, Novartis UK Country President. “White City is quickly becoming one of the UK’s life sciences and technology districts, and the ethos of The WestWorks campus complements how we work to deliver on our strategy to reimagine medicine.”

“At Imperial, we firmly believe that the co-location of academic research and businesses is central to driving innovation and economic growth. This is at the heart of our vision for White City. Novartis is a natural fit for White City’s booming life sciences ecosystem, and we hope that this move will pave the way to new collaborations and partnerships to enhance our work in this area” said Professor David Gann, Vice President (Innovation) at Imperial College London.

Novartis is one of the world’s largest pharmaceutical companies, headquartered in Basel, Switzerland. In 2017, the Group achieved net sales of $49.1 billion, while R&D throughout the Group amounted to approximately $9.0 billion. Novartis Group companies employ approximately 125,000 worldwide, and 1,500 in the UK. In 2017 Novartis invested almost £30million in R&D and is a leading sponsor of clinical trials in the UK.

 

This entry was posted in Hammersmith and Fulham, Trade. Bookmark the permalink.